ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

irinotecan sucrosofate

Also written as “Irinotecan liposome injection”, “PEP02” and “Irinotecan Liposome Injection”.

Its studies are mostly in Pancreatic Neoplasms · Small Cell Lung Carcinoma · Breast Neoplasms · Esophageal Squamous Cell Carcinoma · Cholangiocarcinoma, led by 9 companies.

Drug pageIrinotecan sucrosofate: every studyMany companies study it; this page follows only the 20 they lead. All 79 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jan 18, 202120 company-led studies, 2 open or runningNext primary completion: Dec 1, 2026 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Groupits history only50 open or runningphase 2since Jan 18, 2021Jul 20, 2020none ahead
PharmaEngine50 open or runningphase 2since Dec 18, 2008Dec 18, 2008none ahead
Ipsenits history only40 open or runningphase 3since Mar 9, 2017Dec 19, 2012none ahead
Cardiff Oncologyits history only10 open or runningphase 2since Feb 9, 2021Feb 9, 2021none ahead
Jiangsu HengRui Medicineits history only10 open or runningphase 1since Sep 29, 2021Sep 29, 2021none ahead
Merrimack Pharmaceuticalsits history only10 open or runningphase 3since Dec 14, 2011Dec 14, 2011none ahead
Shanghai Runshi Pharmaceutical Technologyits history only11 open or runningphase 2since Jul 9, 2024Jul 9, 2024none ahead
SONIRE Therapeuticsits history only11 open or runningearly phase 1since Jun 5, 2025Jun 5, 2025Dec 1, 2026early phase 1 · NCT07033689
Sorrento Therapeuticsits history only10 open or runningphase 3since Jul 26, 2019Jul 26, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of PharmaEngine only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 18, 2008First studies: 2 phase 2 studiesFirst studyNCT00813163, NCT00813072
  2. Jul 15, 2009Phase 1 study in Colorectal NeoplasmsNCT00940758 · 18 enrolled · Taiwan
  3. Aug 12, 2016Phase 1 study in Solid TumorNCT02884128 · 16 enrolled
  4. Dec 21, 2018Phase 1 study in Refractory Solid TumorsNCT03810742 · 44 enrolled · Taiwan

TargetBeta

TOP1 →read by rule
“DNA topoisomerase I inhibitor”ChEMBL 37, by rule

Other programs on TOP1

ProgramCompanyFurthest phaseStudies
TopotecanruleGlaxoSmithKlinephase 333

Studies

All 5 PharmaEngine leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03810742Refractory Solid Tumors · Taiwan1CompletedMay 4, 202244
NCT02884128Solid Tumor1CompletedAug 200816
NCT00940758Colorectal Neoplasms · Taiwan1CompletedMay 201218
NCT00813163Pancreatic Neoplasms · United States, Taiwan2CompletedDec 201041
NCT00813072Stomach Neoplasms · Bosnia and Herzegovina, Croatia, Korea, Republic of and more2CompletedJul 2010135

How it is read

Names in the registry

  • “Irinotecan liposome injection”, 5 entries
  • “PEP02”, 4 entries
  • “Irinotecan Liposome Injection”, 3 entries
  • “MM-398”, 2 entries
  • “Nanoliposomal irinotecan”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.